News | October 27, 2021
Cipla consolidated net profit at Rs 711.36 cr. in Q2FY22
Cipla has reported consolidated financial results for the period ended September 30, 2021
Cipla has reported consolidated financial results for the period ended September 30, 2021
Filing marks first protein-based vaccine submitted to MHRA for authorization
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
The new products include the COAG Line automated, semi-automated and POC systems manufactured by Diagon Hungary
The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
Second interchangeable biosimilar product approved by agency
_256_384.jpg)
The platform will be a curated marketplace for sustainable-driven products by small-medium entrepreneurs and will encourage an autonomous marketplace
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
U.S. FDA to decide whether to authorize a booster dose in the coming days
Subscribe To Our Newsletter & Stay Updated
